DavidEMoodyMD

Radiology • Post Falls, ID

Interventional Neuroradiology, Vascular & Interventional Radiology

Physician

Join to view full profile

Dr. Moody is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Moody's full profile

Already have an account?

Office
1300 E Mullan Ave
Post Falls, ID 83854
Phone+1 208-625-5564

Fax+1 208-625-5565
Is this information wrong?

Education & Training

Loma Linda University Health Education ConsortiumFellowship, Interventional Radiology - Independent, 1997 - 1998
Loma Linda University Health Education ConsortiumResidency, Radiology-Diagnostic, 1993 - 1997
Tripler Army Medical CenterInternship, Transitional Year, 1992 - 1993
Loma Linda University School of MedicineClass of 1992

Certifications & Licensure

OR State Medical License 2002 - Present
WA State Medical License 2002 - 2016
ID State Medical License 2002 - 2023
NC State Medical License 1998 - 2004
CA State Medical License 1993 - 2017
HI State Medical License 1993 - 1994
American Board of Radiology Interventional Radiology and Diagnostic Radiology

Publications & Presentations

PubMed

Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (Callithrix jacchus).
Niora J Fabian, David E. Moody, Olga Averin, Wenfang B. Fang, Morgan Jamiel, James G. Fox, Monika Burns, Jennifer L Haupt> ;Journal of The American Association for Laboratory Animal Science. 2021 Jul 19
1 citations
Pharmacokinetics of Buprenorphine and Sustained-release Buprenorphine in Common Marmosets (Callithrix jacchus).
Casey Fitz, Anna Goodroe, David E. Moody, Wenfang B. Fang, Saverio Capuano> ;Journal of The American Association for Laboratory Animal Science. 2021 Mar 1
Analysis for Alpha-Pyrrolidinovalerophenone and Its 2-Oxo-PVP Metabolite in Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
David M. Andrenyak, David E. Moody, Jonathan M Crites, Michael H. Baumann> ;Journal of Analytical Toxicology. 2021 Feb 6
4 citations
Could Postnatal Age–Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life?
Tao Liu, Tamorah R Lewis Md PhD, Jason N. Moore, Walter K. Kraft, Estelle B. Gauda, David Alan Sartori, David E. Moody, Jogarao V. S. Gobburu, Vijay Ivaturi> ;CPT: pharmacometrics & systems pharmacology. 2019 Jul 1
1 citations
The inhibition of first-pass metabolism of ethanol by H2-receptor antagonists: a tabulated review.
David E. Moody> ;Expert Opinion on Drug Safety. 2018 Oct 1
4 citations
Inhibition of In Vitro Metabolism of Opioids by Skeletal Muscle Relaxants.
David E. Moody, Yueqiao Fu, Wenfang B. Fang> ;Basic & Clinical Pharmacology & Toxicology. 2018 Sep 1
6 citations
Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial.
Marisa S. Briones, Steven Shoptaw, Ryan Cook, Matthew J. Worley, Aimee-Noelle Swanson, David E. Moody, Wenfang B. Fang, John Tsuang, Benjamin A. Furst, Keith G. Heinze...> ;Drug and Alcohol Dependence. 2018 Aug 1
17 citations
The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.
Jason N. Moore, Marc R. Gastonguay, Chee M. Ng, Susan C. Adeniyi-Jones, David E. Moody, Wenfang B. Fang, Michelle E. Ehrlich, Walter K. Kraft> ;Clinical Pharmacology & Therapeutics. 2018 Jun 1
21 citations
Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.
David M. Andrenyak, David E. Moody, Matthew H. Slawson, Daniel S. O'Leary, Margaret Haney> ;Journal of Analytical Toxicology. 2017 May 1
Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil
Kenneth Grasing, Deepan Mathur, Cherilyn DeSouza, Thomas F. Newton, David E. Moody, Marc G. Sturgill> ;American Journal on Addictions. 2016 Aug 1
27 citations
Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.
Chee M. Ng, Erin Dombrowsky, Hopi Lin, Michelle E. Erlich, David E. Moody, Jeffrey S. Barrett, Walter K. Kraft> ;Pharmacotherapy. 2015 Jul 1
15 citations
Azole Antifungal Inhibition of Buprenorphine, Methadone and Oxycodone In Vitro Metabolism
David E. Moody, Fenyun Liu, Wenfang B. Fang> ;Journal of Analytical Toxicology. 2015 Jun 1
18 citations
A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Correc...
John F. Carlquist, David E. Moody, Stacey Knight, Eric G. Johnson, Wenfang B. Fang, John A. Huntinghouse, Jeffrey Rollo, Lynn R. Webster, Jeffrey L. Anderson> ;Molecular Diagnosis & Therapy. 2015 Apr 23
6 citations
The Impact of Recent Cocaine Use on Plasma Levels of Methadone and Buprenorphine in Patients with and Without HIV-infection
Jeanette M. Tetrault, Elinore F. McCance-Katz, David E. Moody, David A. Fiellin, Bonnie S. Lruie, An T. Dinh, Lynn E. Fiellin> ;Journal of Substance Abuse Treatment. 2015 Apr 1
11 citations
Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals
Carmen L. Masson, Petrie M. Rainey, David E. Moody, Elinore F. McCance-Katz> ;American Journal on Addictions. 2014 Jan 1
8 citations
In vitro Inhibition of Methadone and Oxycodone Cytochrome P450-Dependent Metabolism: Reversible Inhibition by H2-Receptor Agonists and Proton-Pump Inhibitors
David E. Moody, Fenyun Liu, Wenfang B. Fang> ;Journal of Analytical Toxicology. 2013 Oct 1
18 citations
Determination of Oxycodone, Noroxycodone and Oxymorphone by High-Performance Liquid Chromatography–Electrospray Ionization-Tandem Mass Spectrometry in Human Matrices: ...
Wenfang B. Fang, Michelle R. Lofwall, Sharon L. Walsh, David E. Moody> ;Journal of Analytical Toxicology. 2013 Jul 1
17 citations
Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine
David E. Moody> ;Expert Opinion on Drug Metabolism & Toxicology. 2013 May 14
35 citations
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.
R. Douglas Bruce, David E. Moody, Frederick L. Altice, Marc N. Gourevitch, Gerald Friedland> ;Expert Review of Clinical Pharmacology. 2013 May 1
5 citations
Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
R. Douglas Bruce, David E. Moody, Diane Chodkowski, Laurie Andrews, Wenfang B. Fang, Jerdravee Morrison, Theresa L. Parsons, Gerald Friedland> ;American Journal of Drug and Alcohol Abuse. 2013 Feb 19
36 citations
Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis)
Elizabeth A Nunamaker, Lisa Halliday, David E. Moody, Wenfang B. Fang, Matthew Lindeblad, Jeffrey D Fortman> ;Journal of The American Association for Laboratory Animal Science. 2013 Jan 1
16 citations
Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.
Michelle R. Lofwall, David E. Moody, Wenfang B. Fang, Paul A. Nuzzo, Sharon L. Walsh> ;The Journal of Clinical Pharmacology. 2012 Apr 1
20 citations
Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients
Elinore F. McCance-Katz, David E. Moody, Sudha Prathikanti, Gerald Friedland, Petrie M. Rainey> ;Drug and Alcohol Dependence. 2011 Nov 1
51 citations
The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers
Lisa S. Middleton, Paul A. Nuzzo, Michelle R. Lofwall, David E. Moody, Sharon L. Walsh> ;Addiction. 2011 Aug 1
7 citations
Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
R. Douglas Bruce, David E. Moody, Wenfang B. Fang, Diane Chodkowski, Laurie Andrews, Gerald Friedland> ;American Journal of Drug and Alcohol Abuse. 2011 Jul 13
Join now to see all

Grant Support

Human Metabolism Of Anti-Abuse MedicationsNational Institute On Drug Abuse2002–2005
Human Metabolism Of LAAM: Effects Of Ketoconazole On PharmacokineticsNational Center For Research Resources1999–2002
Human Metabolism Of 1-Alpha-Acetylmethadol (LAAM)National Institute On Drug Abuse1997–1998
Polymorphism In The Metabolism Of Drugs Of AbuseNational Institute On Drug Abuse1988–1992